
    
      The study consists of:

        -  A core treatment period: Teriflunomide 7 mg or Teriflunomide 14 mg or placebo was
           administered in double-blind fashion until a fixed common end date which was
           approximately 48 weeks after randomization of the last participant.

        -  An extension treatment period: the highest dose of teriflunomide was administered in
           open-label fashion to participants who successfully complete the core treatment period
           and wish to continue.

      The overall treatment period was followed by a 4-week elimination follow-up period.
    
  